The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 5 of the 14 sources its claims cite were checked for support.
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.
Open accessAbstract
BACKGROUND: Talquetamab is the first GPRC5D × CD3 bispecific antibody approved for relapsed or refractory multiple myeloma. In phase 1 of the MonumenTAL-1 study, initial results of subcutaneous talquetamab 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks showed preliminary clinical activity. We describe safety and activity results in patients treated with talquetamab, including patients who had received previous T-cell redirection therapy (TCR). This post-hoc analysis was done with more mature median follow-up to evaluate duration of response in patients treated with talquetamab 0·8 mg/kg every 2 weeks. METHODS: MonumenTAL-1 is a multicentre, open-label, phase 1-2 study of talquetamab, phase 1 of which has previously been published. The 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks recommended subcutaneous doses identified in phase 1 were evaluated in phase 2 in patients who were 18 years of age or older, had at least three previous lines of therapy, had an Eastern Cooperative Oncology Group performance status of 0 to 2, and were naive or exposed to previous TCR. The primary endpoint was overall response rate assessed by independent review committee in all patients who received at least one dose of talquetamab. Safety was assessed in all patients who received at least one dose of talquetamab. This study was registered with ClinicalTrials.gov, NCT03399799 (phase 1) and NCT04634552 (phase 2). FINDINGS: Between Jan 3, 2018, and Feb 20, 2023, 735 patients were screened across all phase 1-2 cohorts. Of these, 537 patients screened for inclusion were treated across phase 1 and 2 cohorts, of whom 198 (27%) patients were excluded from the study, most commonly due to not meeting eligibility criteria or not having measurable disease. As of Oct 11, 2023, 375 patients had received recommended talquetamab doses across three groups: 143 (0·4 mg/kg once a week group) and 154 (0·8 mg/kg every 2 weeks group) TCR-naive patients and 78 with previous TCR who received either recommended dose (previous TCR group). 217 (58%) of 375 patients were male and 158 (42%) were female. 325 (87%) of 375 patients were White and 32 (9%) patients were Black. Median follow-up was 25·6 months (IQR 8·5-25·9) in the 0·4 mg/kg once a week group, 19·4 months (9·2-20·7) in the 0·8 mg/kg every 2 weeks group, and 16·8 months (7·6-18·7) in the previous TCR group. Overall response rate was 74% (106 of 143 patients, 95% CI 66-81) in the 0·4 mg/kg once a week group, 69% (107 of 154 patients, 62-77) in the 0·8 mg/kg every 2 weeks group, and 67% (52 of 78 patients, 55-77) in the previous TCR group. Most common adverse events in the 0·4 mg/kg once a week, 0·8 mg/kg every 2 weeks, and previous TCR groups were cytokine release syndrome (113 [79%] of 143 patients, 115 [75%] of 154 patients, and 57 [73%] of 78 patients), taste changes (103 [72%], 110 [71%], and 59 [76%]), and infections (85 [59%], 105 [68%], and 59 [76%]). Most common grade 3-4 adverse events were neutropenia (44 [31%], 33 [21%], and 37 [47%]), anaemia (45 [31%], 40 [26%], and 21 [27%]), and lymphopenia (37 [26%], 40 [26%], and 13 [17%]). Fatal adverse events occurred in five patients in the 0·4 mg/kg once a week group, seven patients in the 0·8 mg/kg every 2 weeks group, and no patients in the previous TCR group; none were related to treatment. INTERPRETATION: Talquetamab continued to demonstrate high overall response rates in heavily pretreated patients with relapsed or refractory multiple myeloma with longer follow-up in this post-hoc analysis. Overall response rate was promising in patients with previous TCR, including therapies targeting BCMA. On-target, off-tumour adverse events were common but led to few treatment discontinuations. FUNDING: Janssen.
Overview
CoChat Summary
TL;DR
In this updated analysis of MonumenTAL-1, subcutaneous talquetamab at 0·4 mg/kg once a week or 0·8 mg/kg every 2 weeks continued to show high overall response rates in heavily pretreated relapsed or refractory multiple myeloma, including in patients with previous T-cell redirection therapy. On-target, off-tumour adverse events were common but led to few treatment discontinuations.
Key findings
- Among 375 patients treated with recommended talquetamab doses, overall response rate was 74% (106 of 143, 95% CI 66–81) with 0·4 mg/kg once a week, 69% (107 of 154, 62–77) with 0·8 mg/kg every 2 weeks, and 67% (52 of 78, 55–77) in the previous T-cell redirection therapy (TCR) group.
- Median duration of response was 9·5 months (95% CI 6·7–13·4) with 0·4 mg/kg once a week and 16·9 months (12·9–not estimable) with 0·8 mg/kg every 2 weeks; 12-month duration of response was 56% (41–69) in the previous TCR group.
- Median progression-free survival was 7·5 months (5·7–9·4), 11·2 months (8·4–16·9), and 7·7 months (4·1–14·5) in the 0·4 mg/kg once a week, 0·8 mg/kg every 2 weeks, and previous TCR groups, respectively; 12-month overall survival rates were 76% (68–83), 77% (69–83), and 74% (62–82).
- Most common adverse events were cytokine release syndrome (113 [79%] of 143, 115 [75%] of 154, and 57 [73%] of 78), taste changes (103 [72%], 110 [71%], and 59 [76%]), and infections (85 [59%], 105 [68%], and 59 [76%]); grade 3–4 neutropenia occurred in 44 (31%), 33 (21%), and 37 (47%). Fatal adverse events occurred in five, seven, and no patients, respectively; none were treatment-related.
Methods
- MonumenTAL-1 is a multicentre, open-label, phase 1–2 study. Phase 2 evaluated subcutaneous talquetamab 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks in adults aged 18 years or older with at least three previous lines of therapy including a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody, ECOG performance status 0–2, and TCR-naive or previous TCR exposure.
- The primary endpoint was overall response rate by independent review committee in all patients who received at least one dose. As of Oct 11, 2023, 735 patients were screened, 537 were treated across phase 1 and 2 cohorts, and 375 received recommended doses: 143 in the 0·4 mg/kg once a week group, 154 in the 0·8 mg/kg every 2 weeks group, and 78 in the previous TCR group. Median follow-up was 25·6 months (IQR 8·5–25·9), 19·4 months (9·2–20·7), and 16·8 months (7·6–18·7), respectively.
- Response was calculated with two-sided exact 95% CIs using the Clopper-Pearson method; Kaplan-Meier methods estimated duration of response, progression-free survival, and overall survival. Post-hoc exploratory analyses included response by baseline characteristics, previous therapy exposure, and TCR subgroups.
Limitations
- The provided text does not include a dedicated limitations section. Evident from the design: this is a post-hoc analysis of an open-label, single-arm study without a comparator, so between-group response comparisons are descriptive.
- The paper states that overall survival data are immature, with medians not yet available.
- The previous TCR group was small (n=78), and several analyses—including previous CAR-T versus bispecific antibody subgroups and time since exposure—were post-hoc/exploratory with wide confidence intervals. Phase 1 did not report immune effector cell-associated neurotoxicity syndrome because those assessments were not conducted in that portion of the study.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 1 Not valid · 5 Not checked · 48 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two patients discontinued due to taste changes (both in the 0·8 mg/kg every 2 weeks group).”
plainstates a causen = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“12-month overall survival rates were 76% (95% CI 68–83)”
plainn = 143- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three patients discontinued treatment due to non-rash skin-related adverse events”
plainstates a causen = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“overall response rate was 67% (52 of 78 patients, 95% CI 55–77)”
plainn = 78- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“74% (62–82)”
plainn = 78- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 56 claims and every source verdict.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 23
- The quote only partly states this claim. 1
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationTeclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citationTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Self-citationElranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664
Self-citationGPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7746 · Cited by 391
Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.138 · Cited by 351
Self-citationCho, S.-F., Anderson, K. C., & Tai, Y.-T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01821 · Cited by 294
Verkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003805 · Cited by 182
Self-citation
Cited by
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 165
Self-citationDual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Kumar, S. K., Mateos, M., Ye, J. C., Atrash, S., Magen, H., Quach, H., Chu, M. P., Trudel, S., Richter, J. R., Rodríguez‐Otero, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2514752 · Cited by 60
Self-citationDhakal, B., Akhtar, O. S., Fandrei, D., Jensen, A. M., Banerjee, R. K., Pan, D., Richard, S., Friend, R. N., Rees, M. J., Costello, P., et al. (2025) · Blood · doi:10.1182/blood.2025029773 · Cited by 49
Self-citationvan de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M. M., Mina, R., Zamagni, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00117-6 · Cited by 33
“7 Although rare, ataxia and balance disorder have been reported in patients receiving talquetemab.”
InfluentialSelf-citationChari, A., van de Donk, N. W. C. J., Dholaria, B., Weisel, K. C., Mateos, M., Goldschmidt, H., Martin, T. G., Morillo, D., Reece, D. E., Rodríguez‐Otero, P., et al. (2025) · Blood · doi:10.1182/blood.2025029360 · Cited by 27
Self-citation
Metadata
- Authors
- Chari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., Mateos, M.-V., Costa, L. J., Caers, J., Rasche, L., Krishnan, A., Ye, J. C., Karlin, L., Lipe, B., Vishwamitra, D., Skerget, S., Verona, R., Ma, X., Qin, X., Ludlage, H., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J. D., Kane, C., Heuck, C., San-Miguel, J., & Moreau, P.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- University of Arkansas for Medical Sciences (US)
- University Medical Center Utrecht (NL)
- Josep Carreras Leukaemia Research Institute (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- University of Alabama at Birmingham (US)
- Centre Hospitalier Universitaire de Liège (BE)
- Universitätsklinikum Würzburg (DE)
- City Of Hope National Medical Center (US)
- University of Michigan (US)
- Hôpital Lyon Sud (FR)
- University of Rochester Medicine (US)
- Janssen (Netherlands) (NL)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Chari, Ajai
- ORCID
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2025-04
- Volume
- 12
- Issue
- 4
- Pages
- e269-e281
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W4408392330
- Cited by
- 116
- References
- 27
- Citations by year
- 2026: 67 · 2025: 48
- FWCI
- 84.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Haematology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (acceptedVersion, other-oa)
- Open Repository and Bibliography (University of Liège) (acceptedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Janssen Research and Development
- Janssen Global Services LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- talquetamab, relapsed/refractory multiple myeloma, CAR T-cell therapy, duration of response, safety, subcutaneous dosing, overall response rate, treatment-emergent adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Treatment Outcome, Antibodies, Bispecific
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. https://app.cochat.ai/papers/10.1016/s2352-3026(24)00385-5
- The paper
- Chari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., Mateos, M.-V., Costa, L. J., Caers, J., Rasche, L., Krishnan, A., Ye, J. C., Karlin, L., Lipe, B., Vishwamitra, D., . . . Moreau, P. (2025). Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(24)00385-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.